Shaping the future of precision oncology
From diagnosis through survivorship, supporting patients across the continuum of care.
01
Scientific Program
From detection to decision-making
Featured oral and poster presentations across the continuum of care, including the latest Signatera evidence.
Browse the schedule →
02
Experience it live
Experience Annotation
Complete longitudinal context at a glance, quickly identify high-priority Signatera positive cases.
Try it today →
03
Natera
Precision Oncology Solutions
Natera’s leading precision oncology portfolio: Signatera, Altera, Latitude, and Empower.
Explore Natera Oncology →
From detection to decision-making
Featured research across the continuum of care, from diagnosis through survivorship.
Complete longitudinal context at a glance
Quickly identify high-priority Signatera™ positive cases.
- 1Longitudinal context, at a glance
View ctDNA trajectories layered with clinical milestones: diagnosis, surgery, therapy response.
- 2Molecular and clinical data, layered
Annotate Signatera™ results with imaging, pathology, and treatment events.
- 3Surface trends faster
Identify molecular relapse and prioritize follow-up across your patient panel.
*Case shown is for illustrative purposes only.
Natera’s leading precision oncology portfolio
A complete suite of solutions across the continuum of care, built on the most extensively validated and published MRD assay.
Ultrasensitive high-fidelity MRD
Signatera™
Residual disease test (MRD)
Most extensively studied, adopted, and reimbursed MRD assay available.
Latitude™
Tissue-free MRD test
Qualitative sensitivity, even when tissue is limited.
Genomic profiling & hereditary risk
Altera™
Tumor genomic profile
Identify clinically actionable tumor biomarkers to support optimal treatment planning.
Empower™
Hereditary cancer test
Detect inherited genetic mutations to guide personalized care & familial risk assessment.
From detection to decision-making
DiagnosisDetect residual diseaseIdentify ctDNA after definitive treatment, before radiographic evidence.
Adjuvant therapyOptimize treatmentGuide escalation, de-escalation, and adjuvant decisions on patient relapse risk.
SurveillanceMonitor over timeTrack response and disease burden across therapy lines with serial measurements.
RelapseIdentify relapse earlierSurface molecular relapse months ahead of standard-of-care imaging.
Connect with our team
Personalized testing can help answer important questions after a cancer diagnosis. Tell us a bit about you and a member of our team will follow up.